TY - JOUR
T1 - Longitudinal assessment of abnormal Papanicolaou test rates among women with HIV
AU - Massad, Leslie S.
AU - Xie, Xianhong
AU - Minkoff, Howard
AU - Kassaye, Seble
AU - Karim, Roksana
AU - Darragh, Teresa M.
AU - Golub, Elizabeth T.
AU - Adimora, Adaora
AU - Wingood, Gina
AU - Fischl, Margaret
AU - Konkle-Parker, Deborah
AU - Strickler, Howard D.
N1 - Funding Information:
Data in this manuscript were collected by the Women’s Interagency HIV Study (WIHS). The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health (NIH). WIHS (Principal Investigators): UAB-MS WIHS (Mirjam-Colette Kempf and Deborah Konkle-Parker), U01-AI-103401; Atlanta WIHS (Ighovwerha Ofotokun and Gina Wingood), U01-AI-103408; Bronx WIHS (Kathryn Anastos and Anjali Sharma), U01-AI-035004; Brooklyn WIHS (Howard Minkoff and Deborah Gustafson), U01-AI-031834; Chicago WIHS (Mardge Cohen and Audrey French), U01-AI-034993; Metropolitan Washington WIHS (Seble Kassaye), U01-AI-034994; Miami WIHS (Margaret Fischl and Lisa Metsch), U01-AI-103397; UNC WIHS (Adaora Adimora), U01-AI-103390; Connie Wofsy Women’s HIV Study, Northern California (Ruth Greenblatt, Bradley Aouizerat, and Phyllis Tien), U01-AI-034989; WIHS Data Management and Analysis Center (Stephen Gange and Elizabeth Golub), U01-AI-042590; Southern California WIHS (Joel Milam), U01-HD-032632 (WIHS I – WIHS IV). The WIHS is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), with additional co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA), and the National Institute on Mental Health (NIMH). Targeted supplemental funding for specific projects is also provided by the National Institute of Dental and Craniofacial Research (NIDCR), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Deafness and other Communication Disorders (NIDCD), and the NIH Office of Research on Women’s Health. WIHS data collection is also supported by UL1-TR000004 (UCSF CTSA), UL1-TR000454 (Atlanta CTSA), P30-AI-050410 (UNC CFAR), and P30-AI-027767 (UAB CFAR). Additional support for data analysis from R01CA174634 and R01CA230331 (H.D.S.).
Publisher Copyright:
Copyright © 2019 The Author(s).
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Objective: To describe longitudinal changes in the prevalence of abnormal Papanicolau testing among women living with HIV.Design:Prospective cohort study with sequential enrollment subcohorts.Methods:Four waves of enrollment occurred in the Women's Interagency HIV Study, the US women's HIV cohort (1994-1995, 2001-2002, 2011-2012, 2013-2015). Pap testing was done at intake, with colposcopy prescribed for any abnormality. Rates of abnormal Pap test results (atypical squamous cells of uncertain significance or worse) and cervical intraepithelial neoplasia grade 2 (CIN2) or worse were calculated. Logistic regression models assessed changes in prevalence across cohorts after controlling for severity of HIV disease and other risk factors for abnormal Pap tests.Results:The unadjusted prevalence of any Pap abnormality was 679/1769 (38%) in the original cohort, 195/684 (29%) in the 2001-2002 cohort, 46/231 (20%) in the 2011-2012 cohort, and 71/449 (16%) in the 2013-2015 cohort. In multivariable analysis, compared with risk in the 1994-1995 cohort, the adjusted risk in the 2001-2002 cohort was 0.79 (95% CI 0.59-1.05), in the 2011-2012 cohort was 0.67 (95% CI 0.43-1.04), and in the 2013-2015 cohort was 0.41 (95% CI 0.27-0.62) with P for trend less than 0.0001.Conclusion:Rates of abnormal cytology among women with HIV have fallen during the past two decades.
AB - Objective: To describe longitudinal changes in the prevalence of abnormal Papanicolau testing among women living with HIV.Design:Prospective cohort study with sequential enrollment subcohorts.Methods:Four waves of enrollment occurred in the Women's Interagency HIV Study, the US women's HIV cohort (1994-1995, 2001-2002, 2011-2012, 2013-2015). Pap testing was done at intake, with colposcopy prescribed for any abnormality. Rates of abnormal Pap test results (atypical squamous cells of uncertain significance or worse) and cervical intraepithelial neoplasia grade 2 (CIN2) or worse were calculated. Logistic regression models assessed changes in prevalence across cohorts after controlling for severity of HIV disease and other risk factors for abnormal Pap tests.Results:The unadjusted prevalence of any Pap abnormality was 679/1769 (38%) in the original cohort, 195/684 (29%) in the 2001-2002 cohort, 46/231 (20%) in the 2011-2012 cohort, and 71/449 (16%) in the 2013-2015 cohort. In multivariable analysis, compared with risk in the 1994-1995 cohort, the adjusted risk in the 2001-2002 cohort was 0.79 (95% CI 0.59-1.05), in the 2011-2012 cohort was 0.67 (95% CI 0.43-1.04), and in the 2013-2015 cohort was 0.41 (95% CI 0.27-0.62) with P for trend less than 0.0001.Conclusion:Rates of abnormal cytology among women with HIV have fallen during the past two decades.
KW - HIV infection in women
KW - Papanicolaou test
KW - Women's Interagency HIV Study
UR - http://www.scopus.com/inward/record.url?scp=85075950061&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075950061&partnerID=8YFLogxK
U2 - 10.1097/QAD.0000000000002388
DO - 10.1097/QAD.0000000000002388
M3 - Article
C2 - 31789890
AN - SCOPUS:85075950061
SN - 0269-9370
VL - 34
SP - 73
EP - 80
JO - AIDS
JF - AIDS
IS - 1
ER -